clinical utility

Stakeholders are working to harmonize strategies for overcoming the challenges faced by new blood-based multi-cancer early detection assays.

The new definition factors in individual patients' outcomes, benefits to health systems, access to clinical trials, and shared decision making with patients.

New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.